Deepinder Goyal partners with Art of Living for Temple

Eternal Founder Deepinder Goyal is partnering with the Art of Living for his new healthcare venture, Temple. This collaboration will measure the effects of different meditation practices through Entropy, which is a new biomarker on Temple.

In a post on X, Deepinder Goyal said, “Entropy is a new biomarker on Temple that also measures your body’s (para)sympathetic state, and we have seen it drop real time during meditation, while HR stays flat. I am looking forward to seeing which meditation practice produces the deepest parasympathetic response.”

Founded in 2024, Temple is a wearable technology that tracks physiological and health signals.

Goyal said he visited Art of Living to measure meditation’s effect on Entropy and added that results of the study with Art of Living will be published soon.

Last month, Temple announced the acquisition of London headquartered longevity medicine venture Longevous as it builds its clinical and scientific capabilities ahead of its launch.

As part of the acquisition, Longevous founders Robert Mohr and Avi Roy, along with their team, will join Temple. Mohr has been appointed Chief Medical Officer at Temple. He is a board-certified physician with nearly two decades of clinical experience and previously worked in emergency medicine before moving into evidence-based longevity medicine.

Roy has joined as Head of Science. He is an Oxford-trained biomedical scientist and has worked at the intersection of longevity science and business. He is a co-founder of Founders Health and UDA and was previously a research fellow at the Centre for the Advancement of Sustainable Medical Innovation at the University of Oxford.

According to Goyal, Mohr and Roy had been testing Temple for two months and worked with its science team to pressure-test its Entropy technology and the data it collects. They also became involved in Temple’s validation work and reviewed its first scientific manuscripts before submission.